Jeffrey A. Medin, PhD, MACC Fund Professor
Medical College of Wisconsin | Department of Pediatrics: Section of Hematology/Oncology/BMT
Jeffrey A. Medin, PhD, MACC Fund Professor, and the research lab, 2017
Jeffrey A. Medin, PhD | MACC Fund Professor
Our goal is to continue our translational research on the development and implementation of novel approaches to ameliorate inherited and acquired disorders.
Mary Faber, PhD | Lab Manager
My responsibility for Dr. Medin is to maintain the lab so it functions productively every day. I am also privileged to have the opportunity to participate in and contribute to the many research projects in the lab. As a scientist, I have been a member of basic science research labs since my undergraduate days, but never in one where the research findings potentially translate to clinical practice so directly. I am excited to be included as a member of this lab and to be working in a research field that is stimulating and inevitably significant.
Everett Tate | Research Associate
I am involved in many projects in the Medin lab ranging from Immunotherapy to Lysosomal Storage Diseases. A clinical background, in addition to many years in research, allows me the privilege of working with many physicians in clinical and translational applications of our research. I am fortunate to be a member of the Medin lab and look forward to future research projects.
Salvatore Molino, PhD | Postdoctoral Fellow
Despite the fact that novel cancer therapies are continually being developed, a cure has remained elusive for many advanced-stage solid tumors. A better understanding of tumor pathophysiology is needed, and this requires study of the key factors involved in cell fate. My studies focus attention on sphingolipids and in particular ceramides, and their role in cancer development. Ceramides are involved in intracellular signaling, apoptosis, senescence, proliferation, and differentiation. They can act as second messengers to initiate apoptosis. Several recent studies indicate that ceramides may have a tumor suppressor role.
I am also interested in understanding the pathophysiology and characteristics of a rare disease, known as Farber disease. Farber disease is caused by a defect in aCDase activity and leads to a pathological accumulation of ceramides. Our laboratory has developed a aCDase deficient mouse model that shows all the pathologic symptoms of Farber disease and accumulates ceramides in various organs (brain, liver, spleen, heart, lungs, and kidneys). This mouse is the first murine model of Farber disease, and study of it is needed to find a cure for patients affected by the disease.
Murtaza Nagree | Project Appointment
I am a graduate student of the University of Toronto working on developing the next generation of gene therapy platforms. I aim to improve vector architecture, to test new transgene delivery vehicles, and to enrich for transgene-harboring cells once they have been introduced into a patient. Currently I utilize Fabry disease as a model for these platforms, but I hope to expand to other diseases.
Robyn Oldham | Project Appointment
I joined the Medin lab through the Department of Medical Biophysics at the University of Toronto because of my interest in cancer research, and particularly immunotherapy. My project as a PhD student involves developing, testing and improving chimeric antigen receptors (CARs), a promising treatment for multiple types of cancer. We are creating novel CARs to optimize efficacy, increase safety, and target new types of cancer, with the aim of bringing these therapies to the clinic.
Fabian Yu | Project Appointment
I joined the Medin lab through the University of Toronto’s Institute of Medical Science Phd Program. Having previously worked on the developmental genetics of the model system C. elegans and experience in the fast paced field of stem cell and regenerative medicine. I wanted to do my PhD work on genetic disorders with the aim of transitional medicine.
Farber disease is a rare devastating lysosome storage disorder that is most commonly seen in children. Farber disease is caused by a deficiency in acid ceramidase and patients typically die at a young age. As of date there is no known cure. Our lab is the first to create a viable mouse model to study Farber disease. My main research is to understand the pathophysiology in various organ systems. My current project is looking at pulmonary, hepatic, and visual systems to understand disease progression. In addition, I am interested in testing substrate reduction therapies to better manage this debilitating disease.